Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity

Cavin, Christophe; Holzhaeuser, D; Scharf, Gerlinde; Constable, Anne; Huber, Wolfgang; Schilter, Benoı̂t

doi:10.1016/s0278-6915(02)00029-7

Cited by 381 publications

(272 citation statements)

References 28 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…Coffee and tea contain numerous substances with potentially anti-mutagenic and antioxidant activities that may play a protective role against cancer including phenolic acids and diterpenes (kahweol and cafestol) in coffee and flavonoids (flavanols and flavonols), lignans and phenolic acids in tea. [20][21][22][23] Epidemiological studies that examined the association between either coffee or tea consumption and gastric cancer risk have shown inconclusive results. Although some case-control and cohort studies indicated no association between coffee consumption and risk of gastric cancer, [24][25][26] others have shown an inverse association or a positive association.…”

mentioning

confidence: 99%

Total, caffeinated and decaffeinated coffee and tea intake and gastric cancer risk: Results from the EPIC cohort study

Sanikini

Dik

Siersema

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

Prospective studies examining the association between coffee and tea consumption and gastric cancer risk have shown inconsistent results. We investigated the association between coffee (total, caffeinated and decaffeinated) and tea consumption and the risk of gastric cancer by anatomical site and histological type in the European Prospective Investigation into Cancer and Nutrition study. Coffee and tea consumption were assessed by dietary questionnaires at baseline. Adjusted hazard ratios (HRs) were calculated using Cox regression models. During 11.6 years of follow up, 683 gastric adenocarcinoma cases were identified among 477,312 participants. We found no significant association between overall gastric cancer risk and consumption of total coffee (HR 1.09, 95%‐confidence intervals [CI]: 0.84–1.43; quartile 4 vs. non/quartile 1), caffeinated coffee (HR 1.14, 95%‐CI: 0.82–1.59; quartile 4 vs. non/quartile 1), decaffeinated coffee (HR 1.07, 95%‐CI: 0.75–1.53; tertile 3 vs. non/tertile 1) and tea (HR 0.81, 95%‐CI: 0.59–1.09; quartile 4 vs. non/quartile 1). When stratified by anatomical site, we observed a significant positive association between gastric cardia cancer risk and total coffee consumption per increment of 100 mL/day (HR 1.06, 95%‐CI: 1.03–1.11). Similarly, a significant positive association was observed between gastric cardia cancer risk and caffeinated coffee consumption (HR 1.98, 95%‐CI: 1.16–3.36, p‐trend=0.06; quartile 3 vs. non/quartile 1) and per increment of 100 mL/day (HR 1.09, 95%‐CI: 1.04–1.14). In conclusion, consumption of total, caffeinated and decaffeinated coffee and tea is not associated with overall gastric cancer risk. However, total and caffeinated coffee consumption may be associated with an increased risk of gastric cardia cancer. Further prospective studies are needed to rule out chance or confounding.

show abstract

mentioning

confidence: 99%

Total, caffeinated and decaffeinated coffee and tea intake and gastric cancer risk: Results from the EPIC cohort study

Sanikini

Dik

Siersema

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…11 Besides a minor decreased distal colon cancer risk among coffee consuming men, we found no significant protective effect of coffee in the present study. It is hypothesized that the possibly protective effect of coffee against CRC found in some studies may be related to antioxidant and antimutagenic effects of phenolic compounds (mainly chlorogenic acid), 6,33 inhibition of colon cancer cell growth by caffeine, 8,9 and cafestol and kahweol mediated reduction of bile acid synthesis 2,34,35 and inhibition of CYP1A2 and NAT2 activity. [36][37][38][39] In addition, caffeine may specifically protect against distal colon cancer by increasing the motility of the distal colon and, as a consequence, lowering carcinogen exposure of colonic epithelial cells.…”

Section: Discussionmentioning

confidence: 99%

“…2 Cut-off points (ml) for tea quintiles were 16, 107, 300 and 514. 3 Low consumption is defined as the lowest quintile within consumers of coffee and tea.…”

Section: Coffee and Tea Consumption And Crc Riskmentioning

confidence: 99%

“…per day unknown, smoking status unknown), and baseline intake of energy from fat, energy from non-fat, alcohol, fibers, dairy products, red meat and processed meat (all continuous). 2 Cut-off points (ml) for coffee quintiles were 100, 230, 450 and 625. 3 Cut-off points (ml) for caffeinated coffee quintiles were 70, 190, 387 and 550.…”

Section: Coffee and Tea Consumption And Crc Riskmentioning

confidence: 99%

See 1 more Smart Citation

Coffee and tea consumption, genotype-basedCYP1A2andNAT2activity and colorectal cancer risk-Results from the EPIC cohort study

et al. 2013

View full text Add to dashboard Cite

Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992–2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype‐based CYP1A2 and NAT2 activity was studied in a nested case–control set of 1,252 cases and 2,175 controls. After a median follow‐up of 11.6 years, 4,234 participants developed CRC (mean age 64.7 ± 8.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95–1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97–1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84–1.11) and tea (HR 0.97, 95% CI 0.86–1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC.

show abstract

“…Epidemiologic studies have suggested that coffee intake may decrease the risk of cancer. Coffee may help protect against cancer through the activity of its anticarcinogenic constituents (Daglia, 2000;Cavin, 2002;Hashimoto, 2004;Rogers, 2007) or polyphenolic compounds (Manach, 2004), which inhibit carcinogenesis through antioxidant, antihormonal, and anti-inflammatory mechanisms (Scalbert, 2005). Cafestol and kahweal, 2 coffee-specific diterpenes, can reduce the genotoxicity of multiple carcinogens (Cavin, 2002).…”

Section: Discussionmentioning

confidence: 99%

Lifestyle Factors Including Diet and Leukemia Development: a Case-Control Study from Mumbai, India

Ganesh

Saoba²,

Sarhade³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity

Cited by 381 publications

References 28 publications

Total, caffeinated and decaffeinated coffee and tea intake and gastric cancer risk: Results from the EPIC cohort study

Total, caffeinated and decaffeinated coffee and tea intake and gastric cancer risk: Results from the EPIC cohort study

Coffee and tea consumption, genotype-basedCYP1A2andNAT2activity and colorectal cancer risk-Results from the EPIC cohort study

Lifestyle Factors Including Diet and Leukemia Development: a Case-Control Study from Mumbai, India

Contact Info

Product

Resources

About